Essential characteristics and functions of SLC25 family in tumor

doi:10.3760/cma.j.issn.1673-422X.2018.09.008

Abstract

Abstract: The solute carrier protein 25 family (SLC25) is one of superfamily in solute carrier protein family. The members of SLC25 family function by transporting various solutes across the mitochondrial membrane. Their substrates vary in property, molecular size and mode of transport, and they closely involve in numerous physiological functions. More and more researches indicate that some members of SLC25 family are abnormally expressed in tumors, and some of them play important roles in the occurrence and development of tumors. For example, some members participate in tumorigenesis by regulating cell metabolism, death and proliferation.

Key words: Neoplasms, Solute carrier family

Cheng Siwei, Hu Jun, Xiong Wujun. Essential characteristics and functions of SLC25 family in tumor[J]. Journal of International Oncology, 2018, 45(8): 548-551.

References

［1］ Palmieri F. The mitochondrial transporter family SLC25: identification, properties and physiopathology［J］. Mol Aspects Med, 2013, 34(23): 465484. DOI: 10.1016/j.mam.2012.05.005. ［2］ Schlessinger A, Khuri N, Giacomini KM, et al. Molecular modeling and ligand docking for solute carrier (SLC) transporters［J］. Curr Top Med Chem, 2013, 13(7): 843856. ［3］ Wang YJ, Khan FI, Xu Q, et al. Recent studies of mitochondrial SLC25: integration of experimental and computational approaches［J］. Curr Protein Pept Sci, 2018, 19(5): 507522. DOI: 10.2174/1389203718666161108095052. ［4］ Palmieri F, Pierri CL, De Grassi A, et al. Evolution, structure and function of mitochondrial carriers: a review with new insights［J］. Plant J, 2011, 66(1): 161181. DOI: 10.1111/j.1365313X.2011.04516.x. ［5］ GutiérrezAguilar M, Baines CP. Physiological and pathological roles of mitochondrial SLC25 carriers［J］. Biochem J, 2013, 454(3): 371386. DOI: 10.1042/BJ20121753. ［6］ Poncet D, Pauleau AL, Szabadkai G, et al. Cytopathic effects of the cytomegalovirusencoded apoptosis inhibitory protein vMIA［J］. J Cell Biol, 2006, 174(7): 985996. DOI: 10.1083/jcb.200604069. ［7］ Wilkins HM, Marquardt K, Lash LH, et al. Bcl2 is a novel interacting partner for the 2oxoglutarate carrier and a key regulator of mitochondrial glutathione［J］. Free Radic Biol Med, 2012, 52(2): 410419. DOI: 10.1016/j.freeradbiomed.2011.10.495. ［8］ Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation［J］. Cell, 2011, 144(5): 646674. DOI: 10.1016/j.cell.2011.02.013. ［9］ Brix B, Mesters JR, Pellerin L, et al. Endothelial cellderived nitric oxide enhances aerobic glycolysis in astrocytes via HIF1αmediated target gene activation［J］. J Neurosci, 2012, 32(28): 97279735. DOI: 10.1523/JNEUROSCI.087912.2012. ［10］ Zhang H, Wang Q, Gu J, et al. Elevated mitochondrial SLC25A29 in cancer modulates metabolic status by increasing mitochondriaderived nitric oxide［J］. Oncogene, 2018, 37(19): 25452558. DOI: 10.1038/s413880180139x. ［11］ Baulies A, Montero J, Matías N, et al. The 2oxoglutarate carrier promotes liver cancer by sustaining mitochondrial GSH despite cholesterol loading［J］. Redox Biol, 2018, 14: 164177. DOI: 10.1016/j.redox.2017.08.022. ［12］ Traba J, Del Arco A, Duchen MR, et al. SCaMC1 promotes cancer cell survival by desensitizing mitochondrial permeability transition via ATP/ADPmediated matrix Ca(2+) buffering［J］. Cell Death Differ, 2012, 19(4): 650660. DOI: 10.1038/cdd.2011.139. ［13］ Dalla Pozza E, Fiorini C, Dando I, et al. Role of mitochondrial uncoupling protein 2 in cancer cell resistance to gemcitabine［J］. Biochim Biophys Acta, 2012, 1823(10): 18561863. DOI: 10.1016/j.bbamcr.2012.06.007. ［14］ Sayeed A, Meng Z, Luciani G, et al. Negative regulation of UCP2 by TGFβ signaling characterizes low and intermediategrade primary breast cancer［J］. Cell Death Dis, 2010, 1: e53. DOI: 10.1038/cddis.2010.30. ［15］ Wong CC, Qian Y, Li X, et al. SLC25A22 promotes proliferation and survival of colorectal cancer cells with KRAS mutations and xenograft tumor progression in mice via intracellular synthesis of aspartate［J］. Gastroenterology, 2016, 151(5): 945960.e6. DOI: 10.1053/j.gastro.2016.07.011. ［16］ Xie J, Zhu XY, Liu LM, et al. Solute carrier transporters: potential targets for digestive system neoplasms［J］. Cancer Manag Res, 2018, 10: 153166. DOI: 10.2147/CMAR.S152951. ［17］ CatalinaRodriguez O, Kolukula VK, Tomita Y, et al. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis［J］. Oncotarget, 2012, 3(10): 12201235. DOI: 10.18632/oncotarget.714. ［18］ Cheng L, Lu W, Kulkarni B, et al. Analysis of chemotherapy response programs in ovarian cancers by the nextgeneration sequencing technologies［J］. Gynecol Oncol, 2010, 117(2): 159169. DOI: 10.1016/j.ygyno.2010.01.041. ［19］ Favre C, Zhdanov A, Leahy M, et al. Mitochondrial pyrimidine nucleotide carrier (PNC1) regulates mitochondrial biogenesis and the invasive phenotype of cancer cells［J］. Oncogene, 2010, 29(27): 39643976. DOI: 10.1038/onc.2010.146. ［20］吕依宣, 王晓娜, 吴金亮, 等. 线粒体二羧基载体蛋白SLC25A10对脑胶质瘤细胞增殖的影响及机制［J］. 上海交通大学学报(医学版), 2016, 36(11): 15811587, 1593. DOI: 10.3969/j.issn.16748115.2016.11.008. ［21］蔺媛媛. SLC25A10抑制肝癌凋亡的作用及机制研究［D］. 大连, 大连医科大学, 2017. ［22］ Tina E, Lindqvist BM, Gabrielson M, et al. The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2positive breast tumors［J］. BMC Cancer, 2012, 12: 350. DOI: 10.1186/1471240712350. ［23］ Lindqvist BM, Farkas SA, Wingren S, et al. DNA methylation pattern of the SLC25A43 gene in breast cancer［J］. Epigenetics, 2012, 7(3): 300306. DOI: 10.4161/epi.7.3.19064. ［24］ Prosén S, Eremo AG, Tsegai AD, et al. Decreased expression of the mitochondrial solute carrier SLC25A43 in basal cell carcinoma compared with healthy skin［J］. Oncol Lett, 2017, 14(2): 22182222. DOI: 10.3892/ol.2017.6452. ［25］ Santandreu FM, Valle A, Fernández de Mattos S, et al. Hydrogen peroxide regulates the mitochondrial content of uncoupling protein 5 in colon cancer cells［J］. Cell Physiol Biochem, 2009, 24(56): 379390. DOI: 10.1159/000257430. ［26］ Gonidi M, Athanassiadou AM, Patsouris E, et al. Mitochondrial UCP4 and bcl2 expression in imprints of breast carcinomas: relationship with DNA ploidy and classical prognostic factors［J］. Pathol, Res Pract, 2011, 207(6): 377382. DOI: 10.1016/j.prp.2011.03.007. ［27］ Chevrollier A, Loiseau D, Reynier P, et al. Adenine nucleotide translocase 2 is a key mitochondrial protein in cancer metabolism［J］. Biochim Biophys Acta, 2011, 1807(6): 562567. DOI: 10.1016/j.bbabio.2010.10.008. ［28］ Wilting SM, de Wilde J, Meijer CJ, et al. Integrated genomic and transcriptional profiling identifies chromosomal loci with altered gene expression in cervical cancer［J］. Genes Chromosomes Cancer, 2008, 47(10): 890905. DOI: 10.1002/gcc.20590.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi. Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer [J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying. Research progress of habitat analysis in radiomics of malignant tumors [J]. Journal of International Oncology, 2024, 51(5): 292-297.